NCT07703371 Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome
| NCT ID | NCT07703371 |
| Status | Recruiting |
| Phase | — |
| Sponsor | JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH |
| Condition | Obesity & Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2026-10-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-06-01 with a primary completion date of 2026-10-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dietary fiber are components in foods that are not digested by human gastrointestinal enzymes (alpha amylase and alpha glucosidase) but are instead broken down and fermented by gut microbes. The byproducts generated during fermentation in the large intestine, primarily short-chain fatty acids (SCFA), bile acids, indoles, and their derivatives, circulate through the circulatory system to the liver, lungs, brain, adipose tissue, and muscles, where they modulate metabolism (suppress lipogenesis and alleviate insulin resistance) and immune function. Individuals who are overweight or obese frequently exhibit gut dysbiosis, characterized by lower SCFA producing commensals. This condition predisposes them to metabolic disorders such as insulin resistance, dyslipidemia, and hypertension, and contributes to conditions including type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease. Preclinical and clinical research have demonstrated that the consumption of fiber-rich foods maintains or restores gut microbiota health and diminishes the risk of metabolic disorders. Kodo millet (Paspalum scrobiculatum), a small millet, is rich in dietary fiber and we have developed a palatable kodo millet porridge beverage enriched with polyphenols and dietary fiber. The purpose of this study is to examine the effects of consuming Kodo millet porridge beverage as a nutritional supplement for 3 months, on gut microbiome richness (composition and diversity) and metabolic health in overweight or obese people.
Eligibility Criteria
Inclusion Criteria * Adults aged 20-60 years. * Willingness to provide informed consent. * Willingness to consume Kodo millet porridge daily for 12 weeks. * No planned changes in diet or physical activity during the study. * Overweight or obese (BMI ≥ 25 kg/m²), placing them at risk for metabolic disorders. Exclusion Criteria * Known allergies to millet or any porridge ingredients. * Individuals who are taking on-counter dietary fiber and probiotics supplements * History of any chronic gastrointestinal diseases (e.g., IBD, gastritis, irritable bowel syndrome). * Pregnant or lactating women. * Antibiotic use in last 3 months. * Alcohol abuse, more than 2 drink per day * Presence and usage of medications for any serious chronic illnesses, including uncontrolled diabetes (HbA1c \> 9), cardiovascular disease (aldosterone antagonists, alpha blockers, alpha-beta blockers, anticoagulants, antiplatelets, angiotensin-converting enzyme inhibitors, angiotensin 2 receptor blockers, beta blockers, calcium channel blockers, diuretics, digoxin) , renal disease, neurological or mental disorders, coagulation disorders, and cancer.
Contact & Investigator
Prerana Shridhar Bhat, MSc
PRINCIPAL INVESTIGATOR
JSS MC,JSS AHER
Frequently Asked Questions
Who can join the NCT07703371 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07703371 currently recruiting?
Yes, NCT07703371 is actively recruiting participants. Contact the research team at preranabhat@jssuni.edu.in for enrollment information.
Where is the NCT07703371 trial being conducted?
This trial is being conducted at Mysore, India.
Who is sponsoring the NCT07703371 clinical trial?
NCT07703371 is sponsored by JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH. The principal investigator is Prerana Shridhar Bhat, MSc at JSS MC,JSS AHER. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.